Exact Mass: 609.2381064

Exact Mass Matches: 609.2381064

Found 205 metabolites which its exact mass value is equals to given mass value 609.2381064, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Dexniguldipine

3-((4,4-Diphenyl-1-piperidinyl)propyl)-5-methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate hydrochloride

C36H39N3O6 (609.2838714)

QYNAD

(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-amino-1-hydroxy-4-(C-hydroxycarbonimidoyl)butylidene]amino}-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene]amino}-1-hydroxypropylidene]amino}butanedioate

C25H35N7O11 (609.239444)

QYNAD is an endogenous pentapeptide with the sequence Gln-Tyr-Asn-Ala-Asp (QYNAD in the international one letter code of amino acids), isolated from the cerebrospinal fluid (CSF) of patients with multiple sclerosis (MS) and Guillain-Barre syndrome (GBS). Immune mediated inflammatory neurological disorders like MS and GBS are characterized by demyelination and axonal damage. QYNAD can reversibly block voltage-gated sodium channels in a concentration-dependent manner. The blocking mechanism is a shift of the steady state inactivation curve of the sodium channels to more negative potentials, as with many local anaesthetics. QYNAD was found to reach concentrations in the CSF of MS or GBS that could subsantially block neuronal sodium channels. (PMID: 11750990) [HMDB] QYNAD is an endogenous pentapeptide with the sequence Gln-Tyr-Asn-Ala-Asp (QYNAD in the international one letter code of amino acids), isolated from the cerebrospinal fluid (CSF) of patients with multiple sclerosis (MS) and Guillain-Barre syndrome (GBS). Immune mediated inflammatory neurological disorders like MS and GBS are characterized by demyelination and axonal damage. QYNAD can reversibly block voltage-gated sodium channels in a concentration-dependent manner. The blocking mechanism is a shift of the steady state inactivation curve of the sodium channels to more negative potentials, as with many local anaesthetics. QYNAD was found to reach concentrations in the CSF of MS or GBS that could subsantially block neuronal sodium channels. (PMID: 11750990).

Niguldipine(+)

3-[3-(4,4-diphenylpiperidin-1-yl)propyl] 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-4,5-dihydropyridine-3,5-dicarboxylate

C36H39N3O6 (609.2838714)

4-(2-{6-amino-2-[1-(2-amino-2-carboxy-ethylamino)-2-carboxy-ethyl]-5-methyl-pyrimidine-4-carbonylamino}-3-hydroxy-3-(1(3)H-imidazol-4-yl)-propionylamino)-3-hydroxy-2-methyl-pentanoic acid

C24H35N9O10 (609.250677)

Val Thr Pro Tyr Met

C28H43N5O8S (609.2832198000001)

Glu Glu Phe Trp

(4S)-4-[(2S)-2-amino-4-carboxybutanamido]-4-{[(1S)-1-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}-2-phenylethyl]carbamoyl}butanoic acid

C30H35N5O9 (609.243466)

Glu Glu Trp Phe

(4S)-4-[(2S)-2-amino-4-carboxybutanamido]-4-{[(1S)-1-{[(1S)-1-carboxy-2-phenylethyl]carbamoyl}-2-(1H-indol-3-yl)ethyl]carbamoyl}butanoic acid

C30H35N5O9 (609.243466)

Glu Phe Glu Trp

(4S)-4-[(2S)-2-[(2S)-2-amino-4-carboxybutanamido]-3-phenylpropanamido]-4-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}butanoic acid

C30H35N5O9 (609.243466)

Glu Phe Trp Glu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carboxybutanamido]-3-phenylpropanamido]-3-(1H-indol-3-yl)propanamido]pentanedioic acid

C30H35N5O9 (609.243466)

Glu Ile Trp Tyr

(4S)-4-amino-4-{[(1S,2S)-1-{[(1S)-1-{[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl}-2-(1H-indol-3-yl)ethyl]carbamoyl}-2-methylbutyl]carbamoyl}butanoic acid